ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeted therapy is a type of treatment that blocks specific oncogenic molecules to diminish cancer growth and invasiveness, such as, trastuzumab (Herceptin) for human epidermal growth factor receptor 2 in breast cancer (33), imatinib (Gleevec) for BCR-Abl in chronic myelogenous leukemia (34), and bevacizumab (Avastin) for vascular endothelia growth factor (VEGF) in colorectal and lung cancer (35).